MedDataX Logo

Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

NCT ID: NCT01224769

Last Updated: 2010-10-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

109 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-09-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed or Refractory Chronic Lymphoproliferative Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bendamustine +/- rituximab

bendamustine +/- rituximab

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bendamustine +/- rituximab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with relapsed or refractory chronic lymphoproliferative disorders
* salvage treatment with bendamustine +/- rituximab
* age ≥ 18 years

Exclusion Criteria

* previous treatment with bendamustine
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gruppo Italiano Studio Linfomi

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emilio Iannitto, MD

Role: STUDY_CHAIR

Gruppo Italiano Studio Linfomi

Fortunato Morabito, MD

Role: STUDY_DIRECTOR

Gruppo Italiano Studio Linfomi

Stefano Luminari, MD

Role: PRINCIPAL_INVESTIGATOR

Gruppo Italiano Studio Linfomi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gruppo Italiano Studio Linfomi

Modena, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RETRO-BENDA

Identifier Type: -

Identifier Source: org_study_id